Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Abroad (travel likely)RecruitingPHASE2

Conditions

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Contact: Study coordinator (Jennifer Ruth, RN, BSN) · ruthj2@upmc.edu · 412-623-8963
Contact: Principal Investigator (Dan P Zandberg, MD)

Study leads

Dan P Zandberg, MD
Principal Investigator
UPMC Hillman Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

Head and Neck Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Beijing, China

A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Head and Neck Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE3

Wuhan, China · Chengdu, China

H101 Plus TACE for r/m HNSCC

Head and Neck Squamous Cell Carcinoma · Oncolytic Virus · TACE

Abroad (travel likely)RecruitingPHASE2

Chengdu, China

A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Toronto, Canada